Skip to main content

What the FDA labels say about taking them together

Tizanidine and zileuton

Tizanidine's FDA label of January 2, 2026 names zileuton in its drug interactions section; the zileuton labels PlainMeds reads (2) do not name tizanidine. The tizanidine label: “Inhibitors other than Fluvoxamine and Ciprofloxacin Because of potential drug interactions, concomitant use of Zanaflex with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than strong CYP1A2 …”

Check it at the source: the tizanidine FDA label on DailyMed (effective January 2, 2026, Legacy Pharma USA, Inc.); the zileuton FDA label on DailyMed (effective July 29, 2022, Strides Pharma Science Limited).

What does the tizanidine label say about zileuton?

Tizanidine label, drug interactions

Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Zanaflex label (Covis Pharma US, Inc, May 5, 2025), drug interactions

Inhibitors other than Fluvoxamine and Ciprofloxacin Because of potential drug interactions, concomitant use of Zanaflex with other CYP1A2 inhibitors, such as zileuton, fluoroquinolones other than strong CYP1A2 inhibitors (which are contraindicated), antiarrhythmics (amiodarone, mexiletine, propafenone, and verapamil), cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Zanaflex label (Covis Pharma US, Inc, May 5, 2025), warnings and precautions

Zanaflex may interfere with everyday activities; sedative effects of Zanaflex, alcohol, and other CNS depressants are additive ( 5.3 , 7.5 , 7.6 ) Hallucinations: consider discontinuation of Zanaflex ( 5.4 ) Less potent inhibitors of CYP1A2: may cause hypotension, bradycardia, or excessive drowsiness, use caution if Zanaflex is used with less potent inhibitors of CYP1A2, e.g., zileuton, other fluoroquinolones, antiarrhythmics, cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine ( 5.5 , 7.3 , 12.3 ) Renal impairment (creatinine clearance < 25 mL/min): use Zanaflex with caution, and monitor closely for dry mouth, somnolence, asthenia and dizziness as indicators of …

Ontralfy label (Rosemont Pharmaceuticals, LLC, October 25, 2025), drug interactions

Concomitant use of Ontralfy with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Source: FDA drug label (Zanaflex, NDA020397), Covis Pharma US, Inc, effective May 5, 2025 (SPL set 043d9e51-bfa2-4add-9058-5ece332f7e99), via openFDA

Source: FDA drug label (Ontralfy, NDA216190), Rosemont Pharmaceuticals, LLC, effective October 25, 2025 (SPL set 7b88c338-c0b7-4c08-bef6-a4ffc2f25df7), via openFDA

Source: FDA drug label (Zanaflex), Legacy Pharma USA, Inc., effective January 2, 2026 (SPL set 60c27d35-7349-4fc6-86ad-70fffdbe3e08), via openFDA; the full label on DailyMed

What does the zileuton label say about tizanidine?

Zileuton's label (effective July 29, 2022) and its 1 other brand-application label do not name tizanidine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Zileuton), Strides Pharma Science Limited, effective July 29, 2022 (SPL set a826d16f-df07-447b-b050-b9a02ea1f89e), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

49Tizanidine generic labelers
5Zileuton generic labelers
TizanidineZileuton
Labeled forMuscle spasms and spasticityAsthma
Boxed warningNoNo
Pharmacy cost (NADAC)$0.0331 per tablet 4 mg tablet$2.05 per tablet 600 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?